ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bioventus Inc. (“Bioventus” or “the Company”) (NASDAQ: BVS) for violations of the federal securities laws.
Investors who purchased the Company's shares pursuant and/or traceable to the Company’s initial public offering conducted on February 11, 2021 (the “IPO”) and/or between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 13, 2023.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Bioventus was suffering from a liquidity crisis. The Company could not sustain its rebate practices. The Company failed to maintain appropriate controls over financial reporting. Based on these facts, the Company’s public statements throughout the IPO and class period were false and materially misleading. When the market learned the truth about Bioventus, investors suffered damages.
